EPO revokes Copaxone patent, clears path for Mylan

17-09-2020

Sarah Morgan

EPO revokes Copaxone patent, clears path for Mylan

ricochet64 / Shutterstock.com

The European Patent Office (EPO) has invalidated and revoked a patent related to Teva’s multiple sclerosis drug Copaxone (glatiramer acetate injection), in a win for Mylan.


EPO, Copaxone, Mylan, patent invalidation, Teva, multiple sclerosis, Technical Board of Appeal, litigation, big pharma, commercial actions

LSIPR